Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

NCT07621783 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-06-02

No results posted yet for this study

Summary

Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.

Conditions

  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)

Interventions

DIAGNOSTIC_TEST

Leucine-rich α2-glycoprotein

Leucine-rich α2-glycoprotein measurement

Sponsors & Collaborators

  • Imelda GI Clinical Research Center

    lead OTHER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07621783 on ClinicalTrials.gov